4:51 PM
 | 
Mar 08, 2019
 |  BC Extra  |  Clinical News

AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in the confirmatory Phase III PROLONG trial to reduce the risk of preterm birth.

On the trial's co-primary endpoints, Makena did not reduce the incidence of preterm delivery at less than 35 weeks (11% vs. 11.5%, p=0.72) or the percentage of patients who met criteria for the prespecified neonatal morbidity and mortality composite index (5.4% vs 5.2%, p=0.84) vs. placebo. AMAG Pharmaceuticals...

Read the full 463 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >